Skip to main content
Premium Trial:

Request an Annual Quote

HDL to Offer BG's Heart Failure Test as Service

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Health Diagnostic Laboratory today said that it has signed an agreement to offer BG Medicine's galectin-3 test as a service to physicians.

The Richmond, Va.-based health management and biomarker-based testing firm, said that it will provide the BG test, which was cleared for marketing by the US Food and Drug Administration in late 2010, to physicians along with its own cardiovascular tests. The test is used as an aid in assessing the prognosis of patients with chronic heart failure.

Financial and other terms of the alliance were not disclosed.

BG's marketing partner, Laboratory Corporation of America, began selling the test in the US in January.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.